Key result
High dose periostin-siRNA significantly inhibited tumor growth and reduced periostin expression compared to untreated controls and low dose treatment (P < 0.05).
Why the study?
Does periostin-siRNA inhibit tumor growth in a nude mouse model of human laryngeal squamous cell carcinoma?
RCT (n=48)
Randomly divided
Does periostin-siRNA inhibit tumor growth in a nude mouse model of human laryngeal squamous cell carcinoma?
Periostin silencing by siRNA significantly inhibits tumor growth in a nude mouse model of laryngeal squamous cell carcinoma, suggesting periostin as a potential therapeutic target.
Answers are grounded in this paper and cite their sources.
Periostin may represent a therapeutic target in laryngeal carcinoma; this animal study leaves open translation to patients.
BACKGROUND: The incidence of laryngeal carcinoma is increasing, however, the mechanism is not fully understood. We aimed to investigate the efficacy of periostin gene silencing by siRNA on tumor inhibition, in a novel nude mouse model of human laryngeal squamous cell carcinoma, and to explore possible inhibitory mechanisms. METHODS: Tumors were established in nude mice by transplantation of LSCC AMC-HN-8 cell line. Forty-eight nude mice were randomly divided into groups of eight each, and treated with high (1.0 OD) or low (0.5 OD) doses of periostin-siRNA or appropriate control solutions. Tumor growth was observed and used to calculate an inhibition rate (%). Routine pathological and electron microscopic examination were used to determine tumor apoptosis and proliferation. Changes in periostin mRNA and protein levels were analyzed. RESULTS: Tumor growth was significantly inhibited in mice treated by high dose periostin-siRNA compared to untreated and those treated with low dose periostin-siRNA (P < 0.05). Pathological examination showed increased tumor necrosis and apoptotic changes in treated mice, which was confirmed by electron microscopy. Periostin mRNA and protein expression were significantly reduced in tumors from mice treated with high dose periostin-siRNA, compared to controls and low-dose periostin-siRNA treatment groups (P < 0.05). CONCLUSION: Periostin silencing was associated with growth inhibition of tumor cells in a nude mouse model of LSCC. The underlying mechanism may be due to receptor-mediated induction of relevant signal transduction pathways that modulate the microenvironment needed for cancer cell survival. Periostin is expected to become a new target for cancer therapy.
No takes yet. Share an insight, caveat, or question.
Ye et al. (2018) conducted an RCT in Human laryngeal squamous cell carcinoma (LSCC) (n=48). Periostin-siRNA vs. Untreated and appropriate control solutions was evaluated on Tumor growth inhibition (p=< 0.05). High dose periostin-siRNA significantly inhibited tumor growth and reduced periostin expression compared to untreated controls and low dose treatment (P < 0.05).
Synapse has enriched 10 related papers. Consider them for comparative context: